The biology and tumour-related properties of monocyte tissue factor

Journal of Pathology

Volumn 193, Issue 1, 2001, Pages 3-12

  Lwaleed, Bashir A ^a   Bass, Paul S ^b   Cooper, Alan J ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Causes of expression; Clinical significance; Monocyte tissue factor; Review; Tissue factor; Tumour biology

Indexed keywords

THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANGIOGENESIS; BIOLOGY; BLOOD; BLOOD CLOTTING; CANCER SURGERY; CELL ACTIVATION; CELL DAMAGE; CELL MEMBRANE; ENDOTHELIUM CELL; FEMALE; GENDER; HUMAN; INFLAMMATORY CELL; INFLAMMATORY DISEASE; MACROPHAGE; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MONOCYTE; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SMOKING; SOLID TUMOR;

BLOOD COAGULATION; GENE EXPRESSION REGULATION; HUMANS; MONOCYTES; NEOPLASMS; THROMBOPLASTIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0035159642     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH770>3.0.CO;2-Z     Document Type: Review

References (145)

1. Affinity purification of human tissue factor. Interaction of factor VII and tissue factor in detergent micelles
2. Purification of human brain tissue factor
3. Initiation of coagulation by tissue factor
4. Tissue factor: Then and now
5. Selective cellular expression of tissue factor in human tissues: Implication for disorders of haemostasis and thrombosis
6. Astrocytes are the primary source of tissue factor in the murine central nervous system: A role for astrocytes in cerebral hemostasis
7. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody
8. Immunohistochemical identification of tissue factor in solid tumours
9. Functional and structural properties of urinary tissue factor
10. The role of leukocytes in the activation of blood coagulation
11. Haemostatic properties of normal and perturbed vascular cells
12. Acute inflammation and microthrombosis induced by endotoxin, interleukin-1, and tumour necrosis factor and their implications in Gram-negative infection
13. Rationale and experimental design for the VA cooperative study of anticoagulant (warfarin) in the treatment of cancer
14. Hemostasis and malignancy
15. Tumour angiogenesis and tissue factor
16. Tissue factor in cancer angiogenesis and metastasis
17. The clinical value of tissue factor assays
18. Tissue factor antigen levels in various biological fluids
19. Urinary tissue factor: A potential marker of disease
20. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation
21. Macrophages and metastasis. A biological approach to cancer therapy. Presidential address
22. The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentration of endotoxin: An assay for detection of endotoxin
23. Stimulation of human leukocyte thromboplastic activity by endotoxin
24. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin
25. Monocyte tissue factor induction by lipopolysaccharide (LPS): Dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing protein
26. Tissue factor expression during monocyte-macrophage differentiation
27. Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro. Two procoagulant activities are produced by peripheral-blood mononuclear-cells
28. Platelet activating factor enhancement of lipopoly-saccharide-induced tissue factor activity in monocytes: Requirement of platelets and granulocytes
29. Granulocytes enhance LPS-induced tissue factor activity in monocytes via an interaction with platelets
30. Lymphocyte co-operation is required for the amplification of macrophage procoagulant activity
31. C5 chemotactic fragment induces leukocyte production of TF activity
32. Immune complex-induced human monocyte procoagulant activity. I. A rapid unidirectional lymphocyte-instructed pathway
33. Leukocyte procoagulant activity in man: An in vitro correlate of delayed-type hypersensitivity
34. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies
35. A mechanism of migration inhibition in delayed-type hypersensitivity reactions II. Lymphokines promote procoagulant activity of macrophages in vitro
36. Clinical significance of increased thromboplastin activity on the monocyte surface - A brief review
37. Bioassay of procoagulant albumin in human plasma
38. Effect of some drugs on thromboplastin (factor III) activity of human monocytes in vitro
39. Generation of procoagulant activity by mononuclear phagocytes: A possible mechanism contributing to blood clotting activation within malignant tissues
40. Factors of the extrinsic pathway of blood coagulation in tumour associated macrophages
41. Cellular regulation of tissue factor
42. Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa-dependent arterial thrombus formation
43. Tissue factor expression during coculture of endothelial cells and monocytes
44. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation
45. Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester
46. Staurosporine blocks down-regulation of monocyte-associated tissue factor
47. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity
48. The role of protein synthesis on the generation of tissue factor activity in leukocytes
49. The structural biology of expression and function of tissue factor
50. Quo vadis macrophage activation - Role of phospholipids in the elicitation of the oxidative burst in macrophages
51. The role of arachidonic acid release and lipoxygenase pathway in lipopolysaccharide-induced thromboplastin activity in monocytes
52. Monocyte vesiculation. A mechanism for dissemination of membrane-associated procoagulant activity and adhesion molecules after stimulation by LPS
53. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human monocytes and a constitutively tissue factor-producing neoplastic cell line
54. Expression of tissue factor procoagulant activity: Regulation by cytosolic calcium
55. Enhancement of mononuclear procoagulant activity by platelet 12-hydroxy-eicosatetraenoic acid
56. 2-release and expression of tissue factor activity by peripheral blood monocytes stimulated with lipopolysaccharide
57. A novel biological effect of platelet factor 4 (PF4): Enhancement of LPS-induced tissue factor activity in monocytes
58. The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay
59. P-selectin induces the expression of TF on monocytes
60. Biology and biochemistry of platelet activating factor
61. Cathepsin G is a strong platelet agonist released by neutrophils
62. Mononuclear cell tissue factor: Cell of origin and requirements for activation
63. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity
64. Transient intermittent lymphocyte activation is responsible for the instability of angina
65. The role of human T cells (and T cell products) for monocyte tissue factor generation
66. The instructor cell for the human procoagulant monocyte response to bacterial lipopolysaccharide is a Leu-3a+ T cell by fluorescence-activated cell sorting
67. Monocyte procoagulant activity as a peripheral marker of clotting activation in cancer patients
68. Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro
69. Oxidized low density lipoprotein enhances lipopolysaccharide-induced tissue factor expression in human monocytes
70. Lipopolysaccharide-induced monocyte procoagulant activity, fibrinopeptide A, and PAI-I levels in persons with high or low levels of HDL-lipoprotein
71. Lipoproteins and the haemostatic system in atherothrombotic disorders
72. Expression of tissue factor and factor VIIa-tissue factor inhibitory activity in endotoxin phorbol ester stimulated U937 monocyte-like cells
73. The present status of tissue factor pathway inhibitor
74. Monocyte tissue factor-like activity in post myocardial infarction patients
75. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation
76. Regulation of monocyte tissue factor activity by allogenic and xenogenic endothelial cells
77. Enhancement of procoagulant activity in stimulated mononuclear blood cells and monocytes by cyclosporin
78. Modulation of tissue factor on human monocytes by cisplatin and adriamycin
79. Glucocorticoids inhibit the generation of leukocyte procoagulant (tissue factor) activity
80. 1 inhibit monocyte procoagulant activity in vitro
81. Cyclosporin A inhibits monocyte tissue factor activation in cardiac transplant recipients
82. Activation of blood coagulation in cancer: Trousseau's syndrome revisited
83. Venous thrombosis during multimodal treatment of primary breast carcinoma
84. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis
85. The thrombogenic effect of drug treatment in women with stage II breast cancer
86. The high responder phenomenon: Enhancement of LPS induced tissue factor activity in monocytes by platelets and granulocytes
87. Cellular interactions in tissue factor expression by blood monocytes
88. Cellular activation in response to physical exercise: The effect of platelets and granulocytes on monocyte reactivity
89. Increased monocyte procoagulant activity with age
90. Procoagulant activity in whole blood from patients with breast and colorectal cancer
91. Assessment of hyper-coagulability in patients with cancer using the Sonoclot analyzer and thromboelastography
92. Thromboplastin activity of mouse peritoneal macrophages
93. Monocyte tissue factor levels in patients with urological tumours: An association between tumour presence and progression
94. The significance of measuring monocyte tissue factor in patients with breast and colorectal cancer
95. The PLAT study: Haemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results
96. White blood cell counts in persons age 65 years or more from the cardiovascular health study: Correlations with baseline clinical and demographic characteristics
97. Activation of factor XII by tobacco glycoprotein
98. The effects of acute smoking on platelet behaviour, fibrinolysis and haemorheology in habitual smokers
99. The endotoxin-induced coagulant activity of human monocytes
100. Tissue factor generation by human mononuclear cells: Effects of endotoxin and dissociation of tissue factor generation from the metagenic response
101. Tissue factor activity in HeLa cells measured with a continuous chromogenic assay ELISA reader
102. Measurement of macrophage cellular procoagulant activity
103. Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes
104. Tissue factor (coagulation factor III) inhibition by apolipoprotein A-II
105. A novel microtiter plate assay for the quantitation of procoagulant activity on adherent monocytes, macrophage and endothelial cells
106. Change in sensitivity to lipopolysaccharide during the differentiation of human monocytes to macrophages in vitro
107. LPS-induced, but not interferon-gamma-induced procoagulant activity of suspended human macrophages is followed by a refractory state of low procoagulant expression
108. Modulation of blood cell activation by four commonly used anticoagulants
109. Shortened endotoxin-activated clotting time in patients with carcinoma
110. An assessment of monocyte procoagulant activity in patients with solid tumours
111. Whole blood procoagulant activity in breast and colorectal cancer
112. The mandatory role of complement in the endotoxin-induced synthesis of thromboplastin in blood monocytes
113. An ELISA for tissue factor using monoclonal antibodies
114. Flow cytometric analysis of tissue factor (TF) expression on stimulated monocytes - Comparison to procoagulant activity of mononuclear blood cells
115. Detection of monocyte tissue factor after endotoxin stimulation: Comparison of one functional and three immunological methods
116. Monocyte procoagulant activity in breast cancer
117. Increased monocyte procoagulant activity independent of the lupus anticoagulant in patients with systemic lupus erythematosus
118. Activation of coagulation and fibrinolysis in patients with lung cancer: Relation to tumour stage and prognosis
119. Haemostatic abnormalities in malignancy, a prospective study of one hundred and eight patients. Coagulation studies
120. Abnormalities of blood coagulation tests in patients with cancer
121. Tumour angiogenesis
122. Endotoxin induced expression of tumour necrosis factor, tissue factor and plasminogen activator inhibitor activity by peritoneal macrophages
123. Cytokine regulation of angiogenesis in breast cancer: The role of tumour-associated macrophages
124. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice
125. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: Paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family
126. In situ detection of expression of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast tissue
127. Molecular mechanisms linking thrombosis and angiogenesis in cancer
128. Vascular permeability factor: A tumour-derived polypeptide which induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration
129. Regulation of extravascular coagulation by micro-vascular permeability
130. 3 integrins., osteopontin and thrombin
131. The angiogenic effect of tissue factor on tumours and wounds
132. Tumour angiogenesis and metastasis - Correlation in invasive breast carcinoma
133. Tissue factor expression in human non-small cell lung carcinoma measured by immunohistochemistry: Correlation between tissue factor and angiogenesis
134. Vascular endothelial growth factor
135. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
136. Pentoxifylline inhibits hypoxia-induced upregulation of tumour cell tissue factor and vascular endothelial growth factor
137. Coagulation activation by MC28 fibrosarcoma cells facilitates lung tumour formation
138. Coagulative properties of cancer
139. Cancer cell procoagulants and their role in malignant disease
140. Monocyte tissue factor in treated Hodgkin's disease
141. Monocyte production of thromboplastin activity in inflammatory and malignant diseases
142. A quantitative study on monocyte procoagulant activity in acute monoblastic and chronic myelomonoctic leukaemias
143. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: A clinical study
144. Lipoprotein associated coagulation inhibitor, factor VII, antithrombin III, and monocyte tissue factor following surgery